FDA Notifies Of Safety Signal In Schizophrenia Drug Trials
The FDA has raised concerns after four deaths were reported in clinical trials involving an investigational drug for treatment-resistant schizophrenia. Newron Pharmaceuticals disclosed the findings.
This matters for patients and researchers evaluating the drug's safety profile. The evidence comes from clinical trial data.
- study
- investigational evenamide in clinical trials
- population
- patients with treatment-resistant schizophrenia
- sponsor
- Newron Pharmaceuticals
Taken from the source as published — check the details before acting on them.
Safety signal
Four deaths were reported among trial participants, prompting the FDA to flag a potential safety issue.
Common questions
What is evenamide used for?
Evenamide is being studied as a treatment for patients with treatment-resistant schizophrenia.
What action has the FDA taken?
The FDA has raised concerns about a potential safety signal following reports of four deaths in clinical trials.
Sources
- Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
